Huadong Medicine Announces Positive Preliminary Results from a Phase รข… study of HDM2005, a ROR1-Targeting ADC
Huadong Medicine Co., Ltd. (hereinafter referred to as “Huadong Medicine”) today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovativeantibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma (cHL). The results […]